PT4070787T - Formulações farmacêuticas - Google Patents

Formulações farmacêuticas

Info

Publication number
PT4070787T
PT4070787T PT221765241T PT22176524T PT4070787T PT 4070787 T PT4070787 T PT 4070787T PT 221765241 T PT221765241 T PT 221765241T PT 22176524 T PT22176524 T PT 22176524T PT 4070787 T PT4070787 T PT 4070787T
Authority
PT
Portugal
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
PT221765241T
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56418608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT4070787(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PT4070787T publication Critical patent/PT4070787T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT221765241T 2015-06-30 2016-06-29 Formulações farmacêuticas PT4070787T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562187113P 2015-06-30 2015-06-30
US201662298373P 2016-02-22 2016-02-22
US201662301429P 2016-02-29 2016-02-29
US201662317286P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
PT4070787T true PT4070787T (pt) 2023-05-22

Family

ID=56418608

Family Applications (4)

Application Number Title Priority Date Filing Date
PT221765241T PT4070787T (pt) 2015-06-30 2016-06-29 Formulações farmacêuticas
PT191992577T PT3607939T (pt) 2015-06-30 2016-06-29 Formulações farmacêuticas compreendendo tenofovir e emtricitabina
PT221765373T PT4070788T (pt) 2015-06-30 2016-06-29 Formulações farmacêuticas
PT167396258T PT3316868T (pt) 2015-06-30 2016-06-29 Formulações farmacêuticas compreendendo tenofovir e emtricitabina

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT191992577T PT3607939T (pt) 2015-06-30 2016-06-29 Formulações farmacêuticas compreendendo tenofovir e emtricitabina
PT221765373T PT4070788T (pt) 2015-06-30 2016-06-29 Formulações farmacêuticas
PT167396258T PT3316868T (pt) 2015-06-30 2016-06-29 Formulações farmacêuticas compreendendo tenofovir e emtricitabina

Country Status (26)

Country Link
US (2) US20180177734A1 (pt)
EP (5) EP3607939B1 (pt)
JP (3) JP6667556B2 (pt)
KR (2) KR102121329B1 (pt)
CN (1) CN107847450A (pt)
AU (3) AU2016287500B2 (pt)
BR (1) BR112017027843A2 (pt)
CA (1) CA2990210C (pt)
CL (1) CL2017003320A1 (pt)
CO (1) CO2017013293A2 (pt)
CU (1) CU20170168A7 (pt)
DO (1) DOP2017000306A (pt)
EA (1) EA201792592A1 (pt)
EC (1) ECSP17084331A (pt)
ES (4) ES2945345T3 (pt)
HK (1) HK1248547A1 (pt)
IL (1) IL256364A (pt)
MA (1) MA50541A (pt)
MX (1) MX2017016806A (pt)
PE (1) PE20180411A1 (pt)
PH (1) PH12017502431A1 (pt)
PL (4) PL3316868T3 (pt)
PT (4) PT4070787T (pt)
SI (4) SI3607939T1 (pt)
SV (1) SV2017005601A (pt)
WO (1) WO2017004244A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201504857SA (en) 2012-12-21 2015-07-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CA2972259A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
PE20181207A1 (es) 2015-11-09 2018-07-23 Gilead Sciences Inc Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
CN116730920A (zh) 2017-02-17 2023-09-12 文涵治疗有限公司 Ag-10的制备方法、其中间体及其盐
WO2018153977A1 (en) * 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
CA3054822A1 (en) 2017-03-20 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv post-exposure prophylaxis
RU2662160C9 (ru) 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
KR20210046708A (ko) 2018-08-17 2021-04-28 에이도스 테라퓨틱스, 인코포레이티드 Ag10의 제형
CN111096954B (zh) * 2018-10-29 2022-09-16 江苏豪森药业集团有限公司 一种用于抗病毒感染的药物组合物及制备方法
CN110251476B (zh) * 2019-08-01 2022-08-09 海思科制药(眉山)有限公司 一种恩曲他滨替诺福韦药物组合物
CN110917197A (zh) * 2019-12-31 2020-03-27 常州恒邦药业有限公司 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
CN117338733B (zh) * 2023-10-12 2024-05-28 杭州和泽坤元药业有限公司 一种富马酸替诺福韦二吡呋酯片及其制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1301519E (pt) 2000-07-21 2015-06-11 Gilead Sciences Inc Profármacos de análogos de nucleótidos de fosfonato e métodos para selecionar e preparar os mesmos
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
DK1583542T3 (da) * 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
SG2014007744A (en) 2009-02-06 2014-05-29 Gilead Sciences Inc Tablets for combination therapy
CN103732594A (zh) 2011-08-16 2014-04-16 吉联亚科学公司 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐
CA2863662A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
WO2015022351A1 (en) * 2013-08-14 2015-02-19 Ratiopharm Gmbh Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
NO2717902T3 (pt) * 2014-06-20 2018-06-23

Also Published As

Publication number Publication date
WO2017004244A1 (en) 2017-01-05
US20180177734A1 (en) 2018-06-28
ES2945345T3 (es) 2023-06-30
HK1248547A1 (zh) 2018-10-19
PL3316868T3 (pl) 2020-10-19
ECSP17084331A (es) 2018-01-31
AU2019210558B2 (en) 2021-04-22
BR112017027843A2 (pt) 2018-09-04
SV2017005601A (es) 2018-05-04
DOP2017000306A (es) 2018-01-15
KR20200067937A (ko) 2020-06-12
KR20180021134A (ko) 2018-02-28
PE20180411A1 (es) 2018-03-01
CA2990210C (en) 2021-01-12
JP6667556B2 (ja) 2020-03-18
PT3607939T (pt) 2022-09-12
PL3607939T3 (pl) 2022-11-07
SI4070787T1 (sl) 2023-07-31
CN107847450A (zh) 2018-03-27
EP3607939A1 (en) 2020-02-12
EP4070788B1 (en) 2023-03-22
JP2021185188A (ja) 2021-12-09
EP3316868A1 (en) 2018-05-09
EP4233846A3 (en) 2023-10-04
EP3316868B1 (en) 2020-02-19
PT4070788T (pt) 2023-06-06
US20170000807A1 (en) 2017-01-05
SI3316868T1 (sl) 2020-04-30
ES2925246T3 (es) 2022-10-14
CO2017013293A2 (es) 2018-05-31
PL4070788T3 (pl) 2023-07-10
KR102313668B1 (ko) 2021-10-19
IL256364A (en) 2018-02-28
AU2019210558A1 (en) 2019-08-15
EA201792592A1 (ru) 2018-06-29
CU20170168A7 (es) 2018-07-05
EP4233846A2 (en) 2023-08-30
EP4070787B1 (en) 2023-03-01
AU2016287500A1 (en) 2018-01-18
EP3607939B1 (en) 2022-06-01
AU2021202009A1 (en) 2021-04-29
KR102121329B1 (ko) 2020-06-17
JP2018519297A (ja) 2018-07-19
SI4070788T1 (sl) 2023-06-30
PT3316868T (pt) 2020-04-21
MA50541A (fr) 2021-04-07
MX2017016806A (es) 2018-05-07
AU2021202009B2 (en) 2023-04-13
PH12017502431A1 (en) 2018-07-02
EP4070787A1 (en) 2022-10-12
ES2945896T3 (es) 2023-07-10
SI3607939T1 (sl) 2022-10-28
PL4070787T3 (pl) 2023-07-24
AU2016287500B2 (en) 2019-05-02
CL2017003320A1 (es) 2018-07-13
CA2990210A1 (en) 2017-01-05
JP6978534B2 (ja) 2021-12-08
EP4070788A1 (en) 2022-10-12
JP2020079304A (ja) 2020-05-28
ES2786549T3 (es) 2020-10-13

Similar Documents

Publication Publication Date Title
IL246978A0 (en) New paracetamol formulations
SI4070788T1 (sl) Farmacevtske formulacije
HK1254343A1 (zh) 藥物製劑
ZA201903101B (en) Pharmaceutical formulations
IL262745A (en) Improved preparations containing drugs
HK1245653A1 (zh) 藥物製劑
ZA201707094B (en) Pharmaceutical formulations
GB201521462D0 (en) Pharmaceutical composition
IL253177B (en) Pharmacy preparation
EP3337463A4 (en) PHARMACEUTICAL FORMULATIONS
GB201515310D0 (en) Pharmaceutical composition
HK1245073A1 (zh) 藥物組合物
GB201520862D0 (en) Pharmaceutical composition
GB201506755D0 (en) Novel pharmaceutical formulation
GB201511246D0 (en) Pharmaceutical formulation
IL271908A (en) Over-compressed pharmaceutical preparations
GB201417589D0 (en) Pharmaceutical Formulations
GB201610440D0 (en) Pharmaceutical formulations
PL3319596T3 (pl) Farmaceutyczne kompozycje
GB201521456D0 (en) Pharmaceutical composition
GB201506598D0 (en) Pharmaceutical compositions
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations